The incidence of head and neck cancer in Europe is about 35 per 100 000 per year in males and 5 per 100 000 in females. The vast majority of head and neck tumours are of squamous cell type. Curative treatment for disease of limited extension consists of radiation therapy and/or surgery. The failure rate of curative treatment varies with the extension of the disease and the origin of the tumour. Five year survival rates may also vary considerably depending on the extension and primary site, with lowest values less than 25% and highest values more than 75%. Chemotherapy is used in the treatment of squamous cell carcinoma of the head and neck either as the only therapeutic modality for advanced or recurrent tumours or as part of a multimodality approach. The chemotherapy regimens most widely used consist of combinations of methotrexate and bleomycin, and more recently, cisplatin or other agents, with response rates in locally advanced disease equal or greater than 50%, but in metastatic disease only 10-25%.
The response and survival of squamous cell carcinoma of the head and neck to chemotherapy may be considerably influenced by characteristics of the patients and/or the tumour, such as performance status, prior therapy, site of origin of the tumour and possibly histological differentiation (Clavel and Mansour, 1991) .
In view of the high recurrence rate after induction chemotherapy and the low response rate in metastatic disease, the screening of potentially useful drugs in squamous cell carcinoma of the head and neck is warranted and might lead to improve current treatment of this frequent tumour.
Rhizoxin is a 16-membered macrocyclic lactone with antifungal activity Kiyoto et al., 1986) . It is produced by and isolated from the pathogenic fungus Rhizopus chinensis, which causes rice seedling blight. The drug has a molecular weight of 625.8 and is poorly soluble (< 1 mg ml-') in water and hydro-alcoholic vehicles, but very soluble (> 100 mg ml-') in organic solvents such as alcohols, dimethyl sulphoxide and chloroform. Rhizoxin has shown activity in vitro and in vivo in a wide variety of tumour models Hendriks et al., 1992) . Rhizoxin inhibits the mitosis of tumour cells in a way similar to vincristine and maytansine (Tsuruo, 1986; Takahashi, 1987) , with a resulting cell cycle block in the G2/M phase. Binding studies showed that rhizoxin bound to the vincristine binding site and not the colchicine binding site, inhibiting polymerisation of tubulin. The drug was also active in several cell lines resistant to vincristine (Tsuruo et al., 1986) . In vitro studies have shown that an intermittent administration of the drug induced a significantly better tumour growth inhibition than a daily dose schedule (Hendriks et al., 1992) .
In a phase I study using an intravenous bolus administration patients were treated with doses ranging from 0.8 to 2.6 mg m-2 single dose every 3 weeks (Bissett et al., 1992 A total of 89 treatment doses were given with a median number of 2 (range 1-11). Responses are given in Table II . Two partial remissions, assessed by CT scan, were observed and confirmed by extramural review. Response duration was 7.5 and 3.5 months respectively. The overall response rate regarding evaluable patients is 8% (95% confidence interval 1-26%). This response rate is 6% regarding all treated patients. One of these responses was documented in a 32-year-old patient suffering from a large ulcerated cervial recurrence of a tongue carcinoma. Rhizoxin was started after documentation of disease progression during carboplatin-5FU chemotherapy. An 82% tumour regression was observed during rhizoxin therapy. This response lasted for 10 weeks. The second responding patient was treated with neo-adjuvant chemotherapy and radiotherapy for a large squamous cell carcinoma of the tongue, and by surgery and radiotherapy at local recurrence 1 year later. The patient then developed cervical lymph node metastases and obtained a partial remission, assessed by CT scan, with rhizoxin. All but one of the 17 courses of rhizoxin given to the responding patients were given at the dose of 1.5 mg m-2.
The most intriguing side-effect of rhizoxin was a severe pain at the tumour site, that could hardly be controlled by intravenous morphines. It occurred mainly in the first cohort of patients treated and led to the amendment in starting dose indicated above. Thirty-four courses were given at the dose of 2.0 mg m-2, all others at lower doses. After lowering the starting dose the side-effect was no longer observed. In total it was seen in 9 of the 32 patients treated (28%), six of whom were taken off the study because of this toxicity.
Further treatment was well tolerated. Haematological toxicity was moderate and consisted of leucocytopenia grades 1-2 in 35 administrations (39%) and grades 3-4 in 15 courses (17%), while thrombocytopenia grades 1-3 was noticed in three courses (3% Rhizoxin has an interesting preclinical profile of anti-tumour activity. A phase I study revealed neutropenia, thrombopenia, mucositis and diarrhoea as dose-limiting toxicities (Bissett et al., 1992) . In the presently reported phase II study, treatment was initially poorly tolerated due to a remarkably severe pain, occurring at tumour sites previously treated with radiotherapy and unrelievable by any analgetic treatment, including intravenous morphines, but reduction of the starting dose resulted in complete disappearance of this side-effect. Similar observations were made in head and neck cancer patients treated with vinca alkaloids. The pathogenetic mechanism related to the observed pain in the tumour sites will need to be elucidated. This side-effect was not noted in patients who had undergone previous radiotherapy for other diseases, but in most of these diseases radiation doses were lower than the common dose used in the treatment of head and neck cancer. Whether the radiation dose has any relation to the observed side-effect cannot be stated for certain, because of the small sample size. Other reasons for poor tolerance were severe mucositis and febrile neutropenia in the first few patients treated at the initial starting dose. After reduction of the starting dose, treatment was well tolerated with a 56% occurrence of mainly uncomplicated leucocytopenia, mild asthenia (27%) and stomatitis (31%). Thrombocytopenia and diarrhoea, dose-limiting toxicities in the phase I study, were only seen in 3% and 7% of the head and neck cancer patients. These lower incidences could be partly related to the lower doses used in the present study.
Only two objective partial remissions (8%) were achieved. Although the preclinical studies did not show any schedule dependency, other schedules may result in better locoregional tolerability and in theory may enable higher doses with higher response rates. This should first be explored in models attempting to unravel the mechanism behind the tumour pain.
